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Background: In Brazil, ventilator-associated pneumonia (VAP) caused by carbapenem resis-
tant  Acinetobacter baumannii and Pseudomonas aeruginosa isolates are associated with
signiﬁcant mortality, morbidity and costs. Studies on the clonal relatedness of these isolates
could lay the foundation for effective infection prevention and control programs.
Objectives: We  sought to study the epidemiological and molecular characteristics of A. bau-
mannii vs. P. aeruginosa VAP in an adult intensive care unit (ICU).
Methods: It was conducted a cohort study of patients with VAP caused by carbapenem resis-
tant  A. baumannii and P. aeruginosa during 14 months in an adult ICU. Genomic studies were
used to investigate the clonal relatedness of carbapenem resistant OXA-23-producing A.
baumannii and P. aeruginosa clinical isolates. The risk factors for acquisition of VAP were also
evaluated. Clinical isolates were collected for analysis as were samples from the environ-
ment and were typed using pulsed ﬁeld gel electrophoresis.logistic regression analysis identiﬁed trauma diagnosed at admissionResults: Multivariate and inappropriate antimicrobial therapy as independent variables associated with the devel-
opment of A. baumannii VAP and hemodialysis as independent variable associated with P.
aeruginosa VAP. All carbapenem resistant clinical and environmental isolates of A. baumannii
were  OXA-23 producers. No MBL-producer P. aeruginosa was detected. Molecular typing
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revealed a polyclonal pattern; however, clone A (clinical) and H (surface) were the most
frequent among isolates of A. baumannii tested, with a greater pattern of resistance than
other isolates. In P. aeruginosa the most frequent clone I was multi-sensitive.
Conclusion: These ﬁndings suggest the requirement of constant monitoring of these microor-
ganisms in order to control the spread of these clones in the hospital environment.
© 2015 Elsevier Editora Ltda. All rights reserved.
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entilator-associated pneumonia (VAP) is one of the most fre-
uent intensive-care-unit (ICU)-acquired infection, with an
ncidence ranging from 6 to 52%,1 and continues to be a major
ause of morbidity, mortality and increased ﬁnancial bur-
en in ICUs.2 The overall rate of VAP is higher in developing
ountries ICUs than that reported from the US ICUs, with rate
f 13.6 vs. 3.3 per 1000 ventilator-days, respectively.3
Non-fermentative Gram-negative bacilli (NF-GNB) mainly
. baumannii and P. aeruginosa,  have emerged as major agents
f VAP4 and the resistance of these organisms to antibiotics,
articularly to carbapenems, has posed important therapeu-
ic challenges. Currently, carbapenems are considered the
ntimicrobials of choice for treatment of serious infections
aused by A. baumannii and P. aeruginosa5 but their efﬁ-
acy is increasingly compromised by resistance as reported
orldwide.6 This resistance has been attributed to the pro-
uction of carbapenem-hydrolysing--lactamase enzymes of
mbler molecular class D (oxacillinases) and B (metallo--
actamases).7
Acinetobacter species, considered organisms of low viru-
ence, have become one of the most difﬁcult nosocomial
athogens to control and treat with an associated mortality of
pproximately 30%.6 P. aeruginosa is a highly virulent microor-
anism and mortality rates range from 40% to more  than 60%.8
t has been reported that multidrug-resistant (MDR) strains of
his organism are associated with a higher rate of mortality
nd that mortality attributed to infection by P. aeruginosa is
onsiderable.9
The objectives of the present study were to investigate the
isk factors of A. baumannii vs. P. aeruginosa VAP in an adult
CU. Furthermore, data on spread of MDR  A. baumannii and P.
eruginosa isolates and their phenotypic and genotypic char-
cteristics are presented in this study.
aterial  and  methods
etting
he Uberlandia Federal University-Hospital Clinic (UFU-HC) is
 530-bed teaching hospital and a 30-bed clinical-surgical ICU
or adults.tudy  design
his prospective cohort study was conducted from April 2011
o June 2012, in a 30-bed clinical-surgical ICU for adults. Allthe medical records of the patients with VAP by A. bauman-
nii and P. aeruginosa admitted to ICU at the time of the study
were analyzed. Adult patients (≥18 years old) with a ﬁrst
episode of VAP by A. baumannii or P. aeruginosa were included
in the study. Clinical isolates for A. baumannii and P. aerugin-
osa were obtained from cultures of endotracheal aspirate (EA)
of patients admitted to the ICU. Patients identiﬁed as having
VAP by A. baumannii were selected for environmental samp-
ling, and samples were collected on surfaces near patients
with VAP, before and after cleaning.
Deﬁnitions
All patients included in this study were monitored for the
development of VAP using clinical and microbiological criteria,
until discharge or death. VAP was deﬁned as a pneumo-
nia occurring 48 h or more  after endotracheal intubation,
with new and/or progressive radiological inﬁltrate, and at
least two of the following features: purulent sputum, tem-
perature higher than 38.5 ◦C or lower than 35 ◦C, leukocyte
count higher than 10000/L or lower than 3000/L; and pos-
itive quantitative culture of the EA (count ≥106 CFU/mL).10
The Clinical Pulmonary Infection Score (CPIS),11 based on six
clinical assessments, was calculated for patients clinically
suspected of VAP on the same day of endotracheal secretions
collection, and all those with CPIS ≥ 6 were included. Patients
developing VAP within the ﬁrst four days of mechanical venti-
lation (MV) were classiﬁed as having early-onset VAP, while
those developing VAP ﬁve or more  days after the initiation
of MV were classiﬁed as having late-onset VAP.12 Previous
antimicrobial therapy was deﬁned as receiving a systemic
antimicrobial agent for at least 48 h within two  weeks preced-
ing collection sputum for culture.13 The antimicrobial therapy
was considered appropriate if all pathogens isolated from cul-
ture were sensitive to it and inappropriate if any pathogen was
resistant to it.13 Multidrug-resistant (MDR) pathogens were
deﬁned as resistant to three or more  classes of antibiotics.14
Data  collection,  clinical  and  environmental  samples
The demographic characteristics including age, gender, under-
lying disease or condition, admission diagnosis, surgery,
Average Severity of Illness Score (ASIS),15 length of hospital
stay, previous use of antibiotics, and discharge status were
obtained from medical charts. The collection of clinical speci-
mens obtained from EA was performed by the nursing staff
and physiotherapists, early in the morning, by probe num-
ber 12, and transported in a sterile tube to the Microbiology
Laboratory of UFU for processing. Environmental isolates of A.
i s . 2 0 1 5;1  9(4):350–357
Table 1 – Speciﬁc primers used in this study.
Gene Sequence Reference
blaOXA-51 F 5′-TAATGCTTTGATCGGCCTTG-3′
R 5′-TGGATTGCACTTCATCTTGG-3′
19
blaOXA-23 F 5′-GATCGGATTGGAGAACCAGA-3′
R 5′-ATTTCTGACCGCATTTCCAT-3′
19
blaOXA-24 F 5′-GGTTAGTTGGCCCCCTTAAA-3′
R 5′-AGTTGAGCGAAAAGGGGATT-3′
19
blaOXA-58 F 5′-AAGTATTGGGGCTTGTGCTG-3′
R 5′-CCCCTCTGCGCTCTACATAC-3′
19
blaOXA-143 F 5′-TGGCACTTTCAGCAGTTCCT-3′
R 5′-TAATCTTGAGGGGGCCAACC-3′
18
blaIMP F 5′-GAATAGRRTGGCTTAAYTCTC-3′
R 5′-CCAAACYACTASGTTATC-3′
20
blaVIM F 5′-GTTTGGTCGCATATCGCAAC-3′
R 5′-AATGCGCAGCACCAGGATAG-3′
20
blaSPM F 5′-CTAAATCGAGAGCCCTGCTTG-3′
R 5′-CCTTTTCCGCGACCTTGATC-3′
20
blaGIM F 5′-TCAATTAGCTCTTGGGCTGAC-3′
R 5′-CGGAACGACCATTTGAATGG-3′
20352  b r a z j i n f e c t d 
baumannii were obtained while the patient occupied the room.
Three surfaces in each room were sampled, before and after
cleaning: bedside table, bed rail, and door knob. At each site,
an area was sampled using a pre-moistened sterile wipe cloth
(7 × 7 cm).
Species  identiﬁcation  and  antimicrobial  susceptibilities
Isolates were identiﬁed by conventional techniques (envi-
ronment/surfaces) and automated systems (clinical spec-
imen), including the Vitek2® system (bioMérieux Vitek
Systems Inc., Hazelwood, MO). Susceptibility testing for clin-
ical specimens was performed using the Vitek2® system,
and the disk diffusion method was employed to evalu-
ate susceptibility of isolates from surfaces. The following
antimicrobial agents were used to evaluate susceptibility
of A. baumannii isolates: amikacin, ampicillin/sulbactam,
cefepime, ciproﬂoxacin, polymyxin B or colistin, genta-
micin, imipenem, and tigecycline. Imipenem, meropenem,
ceftazidime, ciproﬂoxacin, gentamicin, cefepime, amikacin,
polymixin B, and piperacillin/tazobactam were used to eval-
uate susceptibility of P. aeruginosa. All the tests were done
in accordance with the Clinical and Laboratory Standards
Institute16 recommended practices. Since there are no break-
points available for tigecycline for Acinetobacter spp., US Food
and Drug Administration (FDA) tigecycline breakpoints listed
for Enterobacteriaceae (≤2, 4 and ≥8 g/mL for susceptible,
intermediate and resistant strains, respectively) were applied
to Acinetobacter spp. in this study. Pseudomonas aeruginosa ATCC
27853 and Escherichia coli ATCC 25922 were used as quality
control strains. All isolates of A. baumannii were screened for
carbapenemase producing phenotype by the Modiﬁed Hodge
Test (MHT)16 and all isolates of P. aeruginosa were screened
for metallo--lactamases producing phenotype by the double-
disk synergy test (DDST).17
PCR  ampliﬁcation
To assess the presence of blaOXA genes in A. baumannii strains,
the multiplex PCR was performed as previously described by
Higgins et al.18 and Woodford et al.19 and for ampliﬁcation
of the genes encoding Metallo-Beta-lactamases (MBLs) in P.
aeruginosa strains, the multiplex PCR was performed according
to Woodford.20 Ampliﬁcation of the genes was carried out with
PCR using primers described in Table 1.
Molecular  typing
Isolates were typed by pulsed-ﬁeld gel electrophoresis21
(PFGE), following digestion of intact genomic DNA with ApaI
(Invitrogen) for A. baumannii and SpeI (Fermentas) for P. aeru-
ginosa. DNA fragments were separated on 1% (w/v) agarose
gels in 0.5% TBE [Tris–borate–ethylene diamine tetra-acetic
acid (EDTA)] buffer using a CHEF DRIII apparatus (Bio-Rad,
Hercules, CA) with 6 V/cm, pulsed from 5 s to 15 s, for 18 h
at 14 ◦C for A. baumannii and with 6 V/cm, pulsed from 5 s
◦to 35 s, for 17 h at 14 C, for P. aeruginosa.  Gels were stained
with ethidium bromide and photographed under ultraviolet
light. Computer-assisted analysis was performed using BioN-
umerics v.4.0 (Applied Maths, Sint-Martens-Latem, Belgium).blaSIM F 5′-GTACAAGGGATTCGGCATCG-3′
R 5′-TGGCCTGTTCCCATGTGAG-3′
20
Comparison of the banding patterns was accomplished by
the unweighted pair-group method with arithmetic averages
(UPGMA) using the Dice similarity coefﬁcient.
Statistical  analysis
The Chi-square tests or Fisher’s exact test were used to com-
pare discrete variables. Fisher’s exact test was used instead
of the Chi-square test when one or more  expected values in
the 2 × 2 contingency table were equal or less than 5. The
comparison of two quantitative variables was made using the
Mann–Whitney test for nonparametric variables and the Stu-
dent t test for parametric variables. Two-sided tests were used
for all analyses. Multivariate analysis was performed using
multiple logistic regression and the values were included
when signiﬁcance was <0.05 in univariate analysis. All p-value
<0.05 was considered statistically signiﬁcant. The epidemio-
logical data were analyzed through the programs GraphPad
Prism® 5.0 (La Jolla, CA, USA) and BioEstat 5.0 (Tefé, AM,  Brazil).
Ethical  considerations
The Ethics Committee for Human Research of UFU approved
the project under the protocol number 228/11.
Results
During the study period, we enrolled 30 subjects with VAP
caused by A. baumannii and a similar number of subjects with
VAP caused by P. aeruginosa.  Three patients were excluded
from the epidemiological study because the VAP were due
A. baumannii associated to other microorganisms. The demo-
graphic and clinical characteristics, including risk factors and
outcome of patients infected by these bacteria, are shown in
Table 2.
The risk factors for acquiring A. baumannii VAP by univari-
ate analysis (p ≤ 0.05) were: trauma diagnosis at admission,
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Table 2 – Baseline patient characteristics, risk factors and outcome of VAP caused by A. baumannii vs. P. aeruginosa in the
adult ICU of the UFU-HC.
Characteristics Microorganisms p-Value RR (95% CI)
A. baumannii P. aeruginosa
N = 27 (%) N = 30 (%)
Age [mean]; ±SDa 49.89; ±16.84 58.97; ±19.46 0.064 –
Gender, n (%)
Male 21 (77.78) 24 (80.00) 0.837 0.9333 (0.4890–1.781)
Female 6 (22.22) 6 (20.00)
Admission diagnosis
Clinical 7 (25.92) 21 (70.00) 0.001 0.3625 (0.1824–0.7203)
Surgical 2 (7.41) 1 (3.33) 0.599 1.440 (0.6153–3.370)
Trauma 18 (66.67) 8 (26.67) 0.003 2.385 (1.299–4.377)
Cormorbidities
Smoking 7 (25.92) 11 (36.67) 0.384 0.7583 (0.3939–1.460)
Alcoholism 7 (25.92) 6 (20.00) 0.594 1.185 (0.6511–2.155)
Diabetes mellitus 2 (7.41) 6 (20.00) 0.258 0.4900 (0.1430–1.679)
Heart failure 6 (22.22) 15 (50.00) 0.030 0.4898 (0.2359–1.017)
Lung disease 5 (18.52) 4 (13.33) 0.722 1.212 (0.6262–2.346)
Chronic renal failure 5 (18.52) 4 (13.33) 0.722 1.212 (0.6262–2.346)
Old stroke 0 (0.0) 2 (6.66) 0.493 0.0000 (–)
Malignancy 0 (0.0) 1 (3.33) 1.000 0.0000 (–)
Traumatic brain injury 8 (29.63) 4 (13.33) 0.195 1.579 (0.9328–2.673)
ASISb (>4) 13 (48.15) 6 (20.00) 0.024 3.714 (1.152–11.98)
CPISc ≥ 6d 8 (6–10) 7 (6–10) 0.342 –
Tracheostomy 21 (77.78) 17 (56.67) 0.091 1.750 (0.8508–3.600)
Hemodialysis 3 (11.11) 15 (50.00) 0.002 0.2708 (0.09358–0.7838)
Any surgical procedure 20 (74.07) 19 (63.33) 0.384 1.319 (0.6849–2.539)
MDRe pathogen 14 (51.85) 7 (23.33) 0.026 1.846 (1.087–3.135)
Antimicrobial therapy
Inappropriate 21 (77.78) 8 (26.67) 0.000 3.379 (1.606–7.112)
Appropriate 6 (22.22) 22 (73.33)
Empiric antimicrobial therapy
≥2 25 (92.59) 25 (83.33) 0.427 1.750 (0.5250–5.833)
Carbapenems 10 (37.04) 13 (43.33) 0.629 0.8696 (0.4895–1.545)
Cephalosporins (3rd and 4th generation) 25 (92.59) 26 (86.67) 0.673 1.471 (0.4583–4.719)
Aminoglycoside 0 (0.0) 1 (3.33) 1.0000 0.0 (–)
Fluoroquinolones 8 (29.63) 7 (23.33) 0.590 1.179 (0.6609–2.103)
Glycopeptides 19 (70.37) 19 (63.33) 0.779 1.188 (0.6415–2.198)
Colistin 0 (0.0) 4 (13.33) 0.114 0.0 (–)
VAP
Late 20 (74.07) 24 (80.00) 0.594 0.8442 (0.4640–1.536)
Early 7 (25.93) 6 (20.00)
Length in ICU care before VAP (>7 days) 11 (40.75) 20 (66.67) 0.050 0.5766 (0.3281–1.013)
Length in ICU care after VAP (>20 days) 11 (40.75) 11 (36.67) 0.752 1.094 (0.6296–1.900)
ICU length of stay in days (>30) 9 (33.33) 13 (43.33) 0.439 0.7955 (0.4380–1.445)
HC length of stay in days (>60) 8 (29.63) 11 (36.67) 0.574 0.8421 (0.4549–1.559)
Mortality 12 (44.44) 19 (63.33) 0.153 0.6710 (0.3863–1.165)
aSD, standard deviation; bAverage Severity of Illness Score; cClinical Pulmonary Infection Score; dVariables expressed as median (range);
ensiv
s
a
t
p
9
v
(
0
veMultidrug-resistant; VAP, ventilator associated pneumonia; ICU, int
RR (CI), relative risk (conﬁdence interval).
core ASIS >4, MDR, and inappropriate antimicrobial ther-
py. However, after multiple logistic regression analysis only
rauma diagnosis at admission (OR 7.21, 95% CI: 1.62–32.10,
 = 0.001) and inappropriate antimicrobial therapy (OR 17.29,
5% CI: 2.61–114.50, p = 0.003) remained as an independent
ariables associated with the development of A. baumannii VAP
Table 3). For acquiring P. aeruginosa VAP, only hemodialysis (OR
.14, 95% CI: 0.03–0.70, p = 0.017) remained as an independent
ariable associated with the development of VAP (Table 4).e care unit; UFU-HC, Uberlandia Federal University-Hospital Clinic;
Overall, out of 29 clinical isolates of VAP due to A. bauman-
nii, 17 (58.62%) were imipenem-resistant and most (12, 70.59%)
were positive for class D carbapenemase production (MHT).
Screening for resistance genes was performed by multiplex
PCR and all the 12 isolates were OXA-23 producers. No MBL-
producer P. aeruginosa was detected (Table 5).Thirty one (29.5%) of the 126 samples obtained from 21
rooms occupied by an A. baumannii VAP patient were posi-
tive for A. baumannii and the isolates were recovered mainly
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Table 3 – Multivariable regression analysis of risk factors for VAP caused by A. baumannii in patients interned in the adult
ICU of UFU-HC.
Variables OR 95% CI p-Value
Trauma diagnosis admission 7.2122 1.62–32.10 0.001
ASISa (>4) 3.7154 0.85–16.20 0.080
MDRb pathogen 0.6736 0.11–4.02 0.664
Inappropriate antimicrobial therapy 17.2911 2.61–114.50 0.003
tor a
rval.aAverage Severity of Illness Score; bMultidrug-resistant; VAP, Ventila
Federal University-Hospital Clinic; OR, odds ratio; CI, conﬁdence inte
from the bed rail (29.0%) after cleaning. The prevalence of
MDR  organisms was 74.2% (23/31) with eight (25.8%) imipenem
resistant and six (75.0%) positive by the MHT. By PCR, all six
isolates recovered from surface were positive for the presence
of blaOXA-51 and blaOXA-23.
For operational reasons, only 23 A. baumannii and 19 P. aeru-
ginosa strains were typed. This is the ﬁrst study that evaluated
the clonal relationship among samples of A. baumannii from
patients and hospital environment at the ICU studied.
Twenty-three isolates of A. baumannii were analyzed by
PFGE. Most of them were imipenem-resistant (20/23, 86.9%)
and recovered from VAP episodes (17/23, 73.9%). Eight geno-
types with 80% similarity were observed and genotype A (n = 9,
52.9% of clinical isolates) and H (n = 4, 66.6% of surface isolates)
were the most frequent in the unit. In general, we  observed
different genotypes among environmental (H) and clinical
(A) imipenem-resistant A. baumannii isolates and the three
imipenem-susceptible isolates belonged to two other distinct
genotypes (1, F and 2, G) (Table 5).
Based on the antibiotic susceptibility testing, eight antibio-
types (R1–R8) were identiﬁed among A. baumannii isolates
that were genotypically positive for oxacillinases genes. Five
isolates were assigned as antibiotype R1 and were resis-
tant to all antibiotics tested, with the exception of colistin.
The other antibiotypes (R2–R5) ﬁt in the MDR  pattern. These
antibiotypes presented major pulsotypes characterized as
type A in EA isolates and type H in environmental isolates
(Table 5).
A total of 10 PFGE patterns of P. aeruginosa were observed
among the 19 isolates analyzed, also with a polyclonal pattern,
but with three major clones: I (n = 4, 21.1%), A (n = 3, 15.8%),
H (n = 3, 15.8%). Based on the antibiotic susceptibility testing,
nine antibiotypes (R1–R9) were identiﬁed among P. aeruginosa
isolates that were genotypically negative for MBLs genes and
the main pulsotype I presented itself as multi-sensitive or only
resistant to carbapenems (Table 5).
Table 4 – Multivariable regression analysis of risk factors for VA
ICU of UFU-HC.
Variables OR 
Clinical diagnosis admission 0.2671 
Heart failure 0.6279 
Hemodialysis 0.1424 
Length in ICU care before VAP (>7) 0.2913 
VAP, ventilator associated pneumonia; ICU, intensive care unit; UFU-HC
conﬁdence interval.ssociated pneumonia; ICU, intensive care unit; UFU-HC, Uberlandia
Discussion
Ventilator-associated pneumonia caused by A. baumannii and
P. aeruginosa,  particularly those resistant to the carbapen-
ems, are associated with signiﬁcant mortality and morbidity,
adding considerable costs to hospital care.2,4
Risk factors for VAP due to A. baumannii are mainly head
trauma, prolonged hospital stay and prior antibiotic use,1,10
whereas VAP due to P. aeruginosa is diagnosed in immuno-
compromised patients, especially those with neutropenia.22
In our study, the univariate analysis identiﬁed some vari-
ables as signiﬁcant risk factors for acquiring A. baumannii VAP,
but only trauma diagnosis at admission and inappropriate
antimicrobial therapy were independent risks factors for the
development of VAP by A. baumannii.  Likewise, for acquiring P.
aeruginosa VAP, only hemodialysis was an independent factor.
Therapeutic options are limited for A. baumannii and P.
aeruginosa VAP and the antimicrobial resistance in these
organisms are associated with several mechanisms, but
the most important is the production of -lactamases and
has been attributed to the production of carbapenem-
hydrolysing--lactamase enzymes of Ambler molecular class
D (oxacillinases) for A. baumannii, and class B (MBLs) associ-
ated with loss of porins and efﬂux system overexpression for
P. aeruginosa.7
Currently, carbapenems are the antimicrobials of choice for
treating serious infections caused by A. baumannii.6 In Brazil
and elsewhere7,23 carbapenem resistant isolates are mostly
related to -lactamase OXA-23, as detected in all A. baumannii
imipenem resistant isolates recovered in our study.
Although the most important source of A. baumannii is the
infected or colonized patient, a widespread environmental
contamination is often demonstrated24 as seen in our study,
with a more  expressive contamination of the bed rail even
after cleaning (29.0%), questioning the routine of this service
P caused by P. aeruginosa in patients interned in the adult
95% CI p-Value
0.06–1.11 0.069
0.14–2.88 0.549
0.03–0.70 0.017
0.08–1.11 0.071
, Uberlandia Federal University-Hospital Clinic; OR, odds ratio; CI,
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Table 5 – Analysis of phenotypic and genotypic characteristics of A. baumannii and P. aeruginosa isolates.
Ab1 carbapenem-
resistant/susceptible
N  (%)
MHT2 isolates
analyzed/positive
N (%)
PCR3 analyzed
N (%)
PCR product size
bp/gene (isolates)
Antibiotype
(isolates)
Resistance
proﬁle  (isolates)
Major Ab1
pulsotypes/N (%)
Non-major Ab1
pulsotype/N  (%)
Endotracheal aspirate
17/29 (58.6)/
12/29 (41.4)
17  (100.0)/12
(70.6)
a12/17 (70.6) 353pb/blaOXA-51 (12) R1 (5) AN; SAM; GEN; IPM; TGC A/4 (80.0) G/1 (20.0)
501pb/blaOXA-23 (12) R2 (3) SAM; GEN; IPM; TGC A/2 (66.7) D/1 (33.3)
b02/17 (11.8) R3 (1) AN; SAM; GEN; IPM A/1 (100.0) –
353pb/blaOXA-51 (02) R4 (1) AN; SAM; IPM – C/1 (100)
c03/17 (17.6) 501pb/blaOXA-23 (02) R5 (2) SAM; GEN; IPM A/2 (100.0) –
R6 (2) SAM; IPM B/1 (50.0); C/1 (50.0)
353pb/blaOXA-51 (03) R7 (1) SAM G/1 (100.0)
R8 (2) Multi-sensitive F/1 (50.0); G/1 (50.0)
Environment
8/31 (25.8)/
23/31 (74.2)
8  (100.0)/6 (75.0)
6  (75.0) 353pb/blaOXA-51 (6) R2 (1) SAM; GEN; IPM; TGC H/1 (100.0) –
501pb/blaOXA-23 (6) R5 (4) SAM; GEN; IPM H/3 (75.0) G/1 (25.0)
R6 (1) SAM; IPM – E/1 (100.0)
Pa4
carbapenem-
resistant/susceptible
N (%)
DDST5 isolates
ana-
lyzed/positive
N (%)
PCR3 analyzed
N (%)
PCR product size
bp/gene (isolates)
Antibiotype
(isolates)
Resistance
proﬁle (isolates)
Major Pa4
pulsotypes/N (%)
Non-major Pa4
pulsotype/N (%)
Endotracheal aspirate
15/30 (50.0)/
15/30 (50.0)
14 (93.3)/11 (78.6) 14 (100.0) Negative
R1  (1) AN; FEP; CIP; GEN; IPM; MEM; TZP – L/1 (100.0)
R2 (1) FEP; CIP; GEN; IPM; MEM; TZP – C/1(100.0)
R3 (1) FEP; CIP; IPM; MEM; TZP – E/1 (100.0)
R4 (2) FEP; CIP; GEN; IPM; MEM A/2 (100.0) –
R5 (1) FEP; GEN; IPM; MEM A/1 (100.0) –
R6 (6) IPM; MEM H/2 (33.3), I/1 (16.7) C/1 (16.7), E/1 (16.7),
F/1 (16.7)
R7 (2) IPM I/1 (50.0) G/1 (50.0)
R8 (1) MEM – B/1 (100.0)
R9 (4) Multi-sensitive H/1 (25.0), I/2 (50.0) J/1 (25.0)
1Acinetobacter baumannii; 2Modiﬁed Hodge Test; 3Polymerase chain reaction; 4Pseudomonas aeruginosa; 5Double Disk Synergy Test; a12 isolates positive for carbapenemase production (MHT); b2 isolates
negative for carbapenemase production (MHT); c3 isolates carbapenem-susceptible; AN, amikacin; SAM, ampicillin/sulbactam; CIP, ciproﬂoxacin; FEP, cefepime; GEN, gentamicin; IPM, imipenem;
MEM, meropenem; TGC, tigecycline; TZP, piperacillin/tazobactam.
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in the ICU. As the microorganism can survive in dry conditions
and persist for prolonged periods of time, surfaces may be a
reservoir of epidemic strains in outbreaks in ICUs that ceased
only after closing for terminal cleaning and disinfection.25
The diversity of MDR  A. baumannii and P. aeruginosa iso-
lates in our ICU could provide useful information for hospital
infection control. One or more  A. baumannii clones often coex-
ist in ICUs, as seen in our investigation, but different from
other authors26,27 we  have demonstrated the coexistence of
two major PFGE-typed clones (A – clinical and H – envi-
ronmental) of A. baumannii and three of P. aeruginosa (I, A,
H–clinical), reinforcing the clonal diversity of A. baumannii
and P. aeruginosa.  Furthermore, carbapenem-resistance could
be transmitted horizontally highlighting the infection control
measures, such as hand hygiene, that should be strengthened
to reduce the further spread of both microorganisms.9,27 There
is not a single mechanism of polyclonal dissemination and
although this work has not analyzed colonized patients, this
is a puzzle that could indicate endogenous acquisition.28
Person-to-person transmission of carbapenem resistant A.
baumannii carrying blaOXA-23 was indeed identiﬁed in isolates
belonging to the same pulsotype (genotype A) recovered from
different patients. These data suggest that rapid identiﬁcation
of blaOXA-23 by molecular methods is necessary to implement
rigorous infection control programs, justifying more  effective
contact precautions for patients with carbapenem-resistant
strains.6,27
In summary, this study demonstrates high VAP rates
caused by A. baumannii and P. aeruginosa in an adult ICU
of our hospital mainly associated with the severity of the
underlying disease in patients with P. aeruginosa and inap-
propriate therapy for patients with A. baumannii.  Moreover,
PFGE revealed the polyclonal spread of OXA-23-producing A.
baumannii, isolated also in the environment, and P. aerugin-
osa resistant to carbapenems. Taken together, these results
suggest the requirement of an epidemiological surveillance to
control the transmission of these resistance mechanisms in
the hospital environment.
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